Corbus Pharmaceuticals Announces Abstracts Accepted for Presentation at ASCO 2026 Featuring Updated Clinical Data for CRB-701
Corbus Pharmaceuticals announced that updated clinical data from its Phase 1/2 study of CRB-701 will be presented at the ASCO 2026 Annual Meeting, covering head and neck and cervical cancers. The company provided developmental guidance, expecting to initiate a registrational study for CRB-701 in second-line HNSCC by mid-2026 and report combination data with Keytruda in Q4 2026.
Key figures
- Drug Name
- CRB-701 (SYS6002)
- Phase Of Trial
- Phase 1/2
- Conference dates
- May 29 – June 2
- Combo data readout
- Q4 2026
- Abstract availability
- May 21, 2026
- Registrational study start
- mid-2026
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.